Name
Implementation and Evaluation of New Mexico’s PDMP Mandate Legislation in Context
Date & Time
Wednesday, April 4, 2018, 2:00 PM - 3:15 PM
Speakers
Michael Landen, MD, MPH, State Epidemiologist, New Mexico Department of Health
Kathryn Lowerre, PhD, MPH, Evaluator, New Mexico Department of Health
Kathryn Lowerre, PhD, MPH, Evaluator, New Mexico Department of Health
Description
NEW LOCATION: HANOVER AB
Moderator: Sarah Bacon, PhD, Team Lead, State Opioid Overdose Prevention State Support Team, Centers for Disease Control and Prevention
CE Certified By: AMA,AAFP,ACPE,ANCC,ADA
In March 2016, legislation was passed in New Mexico requiring providers to obtain a prescription drug monitoring program (PDMP) report before initially prescribing an opioid and check established patients quarterly. Although the PDMP mandate did not take effect until January 2017, quarterly data shows that PDMP enrollments and activity have increased substantially since providers became aware of impending changes to their licensing board rules. These data also show marked declines in the percent of overlapping opioid prescriptions from different providers (down 13%) and overlapping opioid and benzodiazepine prescriptions (down 11%). Provider engagement with the PDMP was further enhanced by the introduction of prescriber feedback reports (PFRs) in November 2016.
Presenters will share New Mexico's initial 2017 evaluation findings triangulating multiple sources: PFR surveys, PDMP usage statistics and surveillance data supplemented by interviews with key stakeholders. An unexpected benefit of the PDMP mandate legislation on opioids was the addition of benzodiazepines to reporting requirement rules promulgated by all state licensing boards. Presenters will outline next steps as the state continues to evaluate the impact of the policy change through PDMP user surveys (pharmacists, prescribers, law enforcement) and compare pre/post mandate PDMP data plus drug overdose morbidity and mortality data to create a comprehensive state assessment.
UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO:
- Describe how New Mexico findings relate to previous studies of PDMP mandates in Kentucky, Ohio, Tennessee and New York.
- Explain how the New Mexico mandatory PDMP use legislation was passed and how it is being implemented.
- Identify the strategies New Mexico is using to evaluate the impact of the prescriber mandate legislation in context.
Moderator: Sarah Bacon, PhD, Team Lead, State Opioid Overdose Prevention State Support Team, Centers for Disease Control and Prevention
CE Certified By: AMA,AAFP,ACPE,ANCC,ADA
In March 2016, legislation was passed in New Mexico requiring providers to obtain a prescription drug monitoring program (PDMP) report before initially prescribing an opioid and check established patients quarterly. Although the PDMP mandate did not take effect until January 2017, quarterly data shows that PDMP enrollments and activity have increased substantially since providers became aware of impending changes to their licensing board rules. These data also show marked declines in the percent of overlapping opioid prescriptions from different providers (down 13%) and overlapping opioid and benzodiazepine prescriptions (down 11%). Provider engagement with the PDMP was further enhanced by the introduction of prescriber feedback reports (PFRs) in November 2016.
Presenters will share New Mexico's initial 2017 evaluation findings triangulating multiple sources: PFR surveys, PDMP usage statistics and surveillance data supplemented by interviews with key stakeholders. An unexpected benefit of the PDMP mandate legislation on opioids was the addition of benzodiazepines to reporting requirement rules promulgated by all state licensing boards. Presenters will outline next steps as the state continues to evaluate the impact of the policy change through PDMP user surveys (pharmacists, prescribers, law enforcement) and compare pre/post mandate PDMP data plus drug overdose morbidity and mortality data to create a comprehensive state assessment.
UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO:
- Describe how New Mexico findings relate to previous studies of PDMP mandates in Kentucky, Ohio, Tennessee and New York.
- Explain how the New Mexico mandatory PDMP use legislation was passed and how it is being implemented.
- Identify the strategies New Mexico is using to evaluate the impact of the prescriber mandate legislation in context.
Location Name
Hanover AB
Full Address
Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, Georgia 30303
United States
265 Peachtree St NE
Atlanta, Georgia 30303
United States